Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.

Publication Type:

Journal Article


Advanced drug delivery reviews, Volume 62, Issue 3, p.346-61 (2010)


Animalsdigestive disease, digestive deseases Antineoplastic Agentsdigestive disease, digestive deseases Drug Delivery Systemsdigestive disease, digestive deseases Golddigestive disease, digestive deseases Humansdigestive disease, digestive deseases Metal Nanoparticlesdigestive disease, digestive deseases Nanotechnologydigestive disease, digestive deseases Pancreatic Neoplasmsdigestive disease, digestive deseases Particle Sizedigestive disease, digestive deseases Surface Plasmon Resonance


The targeted delivery of a drug should result in enhanced therapeutic efficacy with low to minimal side effects. This is a widely accepted concept, but limited in application due to lack of available technologies and process of validation. Biomedical nanotechnology can play an important role in this respect. Biomedical nanotechnology is a burgeoning field with myriads of opportunities and possibilities for advancing medical science and disease treatment. Cancer nanotechnology (1-100 nm size range) is expected to change the very foundations of cancer treatment, diagnosis and detection. Nanomaterials, especially gold nanoparticles (AuNPs) have unique physico-chemical properties, such as ultra small size, large surface area to mass ratio, and high surface reactivity, presence of surface plasmon resonance (SPR) bands, biocompatibility and ease of surface functionalization. In this review, we will discuss how the unique physico-chemical properties of gold nanoparticles may be utilized for targeted drug delivery in pancreatic cancer leading to increased efficacy of traditional chemotherapeutics.